| Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency VA Evans, RM Van Der Sluis, A Solomon, A Dantanarayana, C McNeil, ... Aids 32 (11), 1491-1497, 2018 | 161 | 2018 |
| Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy EE To, R Vlahos, R Luong, ML Halls, PC Reading, PT King, C Chan, ... Nature Communications 8 (1), 69, 2017 | 133 | 2017 |
| An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection A Duverger, F Wolschendorf, M Zhang, F Wagner, B Hatcher, J Jones, ... Journal of virology 87 (4), 2264-2277, 2013 | 119 | 2013 |
| TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS‐CoV‐2 infection RM van der Sluis, LB Cham, A Gris‐Oliver, KR Gammelgaard, ... The EMBO journal 41 (10), e109622, 2022 | 58 | 2022 |
| Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes RM van der Sluis, T van Montfort, G Pollakis, RW Sanders, D Speijer, ... PLoS pathogens 9 (3), e1003259, 2013 | 57 | 2013 |
| Combination immune checkpoint blockade to reverse HIV latency RM Van der Sluis, NA Kumar, RD Pascoe, JM Zerbato, VA Evans, ... The Journal of Immunology 204 (5), 1242-1254, 2020 | 54 | 2020 |
| Diverse effects of interferon alpha on the establishment and reversal of HIV latency RM Van der Sluis, JM Zerbato, JW Rhodes, RD Pascoe, A Solomon, ... PLoS pathogens 16 (2), e1008151, 2020 | 44 | 2020 |
| Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection M Centlivre, N Legrand, R Steingrover, R van der Sluis, ML Grijsen, ... Journal of leukocyte biology 89 (5), 785-795, 2011 | 41 | 2011 |
| Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets EJ Heeregrave, MJ Geels, JM Brenchley, E Baan, DR Ambrozak, ... Virology 393 (1), 24-32, 2009 | 41 | 2009 |
| Latency profiles of full length HIV-1 molecular clone variants with a subtype specific promoter RM van der Sluis, G Pollakis, ML van Gerven, B Berkhout, RE Jeeninga Retrovirology 8, 1-12, 2011 | 36 | 2011 |
| Establishment and molecular mechanisms of HIV-1 latency in T cells RM van der Sluis, RE Jeeninga, B Berkhout Current opinion in virology 3 (6), 700-706, 2013 | 32 | 2013 |
| Quantitation of HIV-1 DNA with a sensitive TaqMan assay that has broad subtype specificity RM van der Sluis, T van Montfort, M Centlivre, NCT Schopman, ... Journal of virological methods 187 (1), 94-102, 2013 | 26 | 2013 |
| Antiviral potential of the antimicrobial drug atovaquone against SARS-CoV-2 and emerging variants of concern ME Carter-Timofte, R Arulanandam, N Kurmasheva, K Fu, G Laroche, ... ACS infectious diseases 7 (11), 3034-3051, 2021 | 22 | 2021 |
| Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway T van Montfort, R van der Sluis, G Darcis, D Beaty, K Groen, AO Pasternak, ... EBioMedicine 42, 97-108, 2019 | 20 | 2019 |
| Myeloid dendritic cells induce HIV latency in proliferating CD4+ T cells NA Kumar, RM van der Sluis, T Mota, R Pascoe, VA Evans, SR Lewin, ... The Journal of Immunology 201 (5), 1468-1477, 2018 | 19 | 2018 |
| Plasmacytoid dendritic cells during COVID-19: Ally or adversary? RM Van der Sluis, CK Holm, MR Jakobsen Cell Reports 40 (4), 2022 | 18 | 2022 |
| Interplay between viral Tat protein and c-Jun transcription factor in controlling LTR promoter activity in different human immunodeficiency virus type I subtypes RM van der Sluis, R Derking, S Breidel, D Speijer, B Berkhout, ... Journal of General Virology 95 (4), 968-979, 2014 | 17 | 2014 |
| Plasmacytoid dendritic cells as cell-based therapeutics: A novel immunotherapy to treat human immunodeficiency virus infection? REM Van der Sluis, JH Egedal, MR Jakobsen Frontiers in cellular and infection microbiology 10, 249, 2020 | 16 | 2020 |
| Memory CD4+ T cells that co-express PD1 and CTLA4 have reduced response to activating stimuli facilitating HIV latency TA Rasmussen, JM Zerbato, A Rhodes, C Tumpach, A Dantanarayana, ... Cell Reports Medicine 3 (10), 2022 | 14 | 2022 |
| CD4-and time-dependent susceptibility of HIV-1-infected cells to antibody-dependent cellular cytotoxicity WS Lee, J Prévost, J Richard, RM van der Sluis, SR Lewin, M Pazgier, ... Journal of Virology 93 (10), 10.1128/jvi. 01901-18, 2019 | 14 | 2019 |
